专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2006110601A2 THE GENETIC RISK ASSESSMENT IN HEART FAILURE: IMPACT OF THE GENETIC VARIATION OF NOS3 审中-公开
标题翻译：心脏遗传危险评估：NOS3遗传变异的影响
公开(公告)号：WO2006110601A2
公开(公告)日：2006-10-19
申请号：PCT/US2006013185
申请日：2006-04-07
申请人： NITROMED INC , UNIV PITTSBURGH , WORCEL MANUEL , SABOLINSKI MICHAEL , TAM SANG W , MCNAMARA DENNIS M
发明人： WORCEL MANUEL , SABOLINSKI MICHAEL , TAM SANG W , MCNAMARA DENNIS M
IPC分类号： A61K31/21 , C12Q1/68
CPC分类号： A61K31/34 , A61K31/502 , A61K45/06 , A61K2300/00
摘要： The invention provides methods for (a) reducing mortality associated with heart failure; (b) improving oxygen consumption; (c) treating heart failure; (d) treating hypertension; (e) improving the quality of life in a heart failure patient; (f) inhibiting left ventricular remodeling; (g) reducing hospitalizations related to heart failure; (h) improving exercise tolerance; (j) increasing left ventricular ejection fraction; (k) decreasing levels of B-type natriuretic protein; (1) treating renovascular diseases; (m) treating end-stage renal diseases; (n) reducing cardiomegaly; (o) treating diseases resulting from oxidative stress; (p) treating endothelial dysfunctions; (q) treating diseases caused by endothelial dysfunctions; (r) treating cardiovascular diseases; in a patient in need thereof, wherein the patient has at least one polymorphism in the endothelial nitric oxide synthase (NOS3) gene, comprising administering to the patient (i) at least one antioxidant compound or a pharmaceutically acceptable salt thereof; (ii) at least one nitric oxide enhancing compound; and (iii) optionally the best current therapy for the treatment of cardiovascular diseases. In one embodiment the antioxidant is a hydralazine compound or a pharmaceutically acceptable salt thereof and the nitric oxide enhancing compound is isosorbide dinitrate and/or isosorbide mononitrate.
摘要翻译：本发明提供了（a）降低与心力衰竭相关的死亡率的方法; （b）提高耗氧量; （c）治疗心力衰竭; （d）治疗高血压; （e）改善心力衰竭患者的生活质量; （f）抑制左心室重构; （g）减少与心力衰竭有关的住院; （h）提高运动耐力; （j）增加左心室射血分数; （k）B型利尿钠蛋白水平降低; （1）治疗血管性疾病; （m）治疗终末期肾病; （n）减轻心脏肥大; （o）治疗由氧化应激引起的疾病; （p）治疗内皮功能障碍; （q）治疗由内皮功能障碍引起的疾病; （r）治疗心血管疾病; 在患有需要的患者中，其中所述患者在所述内皮一氧化氮合酶（NOS3）基因中具有至少一种多态性，其包括给予所述患者（i）至少一种抗氧化剂化合物或其药学上可接受的盐; （ii）至少一种一氧化氮增强化合物; 和（iii）任选的治疗心血管疾病的最佳治疗方法。在一个实施方案中，抗氧化剂是肼屈嗪化合物或其药学上可接受的盐，并且一氧化氮增强化合物是硝酸异山梨酯和/或一硝酸异山梨酯。

IPRDB

热门服务

关于我们

友情链接

联系方式